Abstract
The NUS1 gene was recently associated with Parkinson’s disease (PD) in the Chinese population. Here, as part of the International Parkinson’s Disease Genomics Consortium (IPDGC), we have leveraged large-scale PD case-control cohorts to comprehensively assess the NUS1 association in individuals of European descent. Burden analysis of rare nonsynonymous damaging variants across case-control individuals from whole-exome and -genome datasets did not find evidence of NUS1 association with PD. Overall, single variant tests for rare (MAF<0.01) and common (MAF>0.01) variants, including 15 PD-GWAS cohorts and summary statistics from the largest PD GWAS meta-analysis to date, also did not uncover any associations. Our results indicate a lack of evidence for a role of rare damaging nonsynonymous NUS1 variants in PD in unrelated case-control cohorts of European descent, suggesting that the previously observed association could be driven by extremely rare population-specific variants.
Competing Interest Statement
D.K. is the Founder and Scientific Advisory Board Chair of Lysosomal Therapeutics Inc. D.K. serves on the scientific advisory boards of The Silverstein Foundation, Intellia Therapeutics, and Prevail Therapeutics and is a Venture Partner at OrbiMed. B.I.B, S.J.L, S.B.G., N.E.M., Z.G.O and J.R.G. declare that they do not have conflict of interests.
Funding Statement
D.K. is supported by the Simpson Querrey Center for Neurogenetics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As analyses utitlize secondary analyses of suitably anonymized datasets, they do not require ethics committee review. The respective ethical committees for medical research approved involvement in genetic studies and all participants gave written informed consent in the original publications for the datasets used.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All datasets used in the present study are publicly available from the respective studies and databases. The IPDGC datasets including whole-exome sequencing, GWAS and summary statistics from the 2019 PD meta-analysis were obtained from https://pdgenetics.org/resources. The AMP-PD whole-genome sequencing cohort was obtained from https://amp-pd.org/.
